Deadline for Abstract Submission : May 9(FRI), 2025
Notification of Acceptance : July 7 (MON), 2025
Submitted abstracts will be reviewed by the Scientific Program Committee. The presentation type may possibly be changed following review by the Scientific Committee.
Abstract submission does not constitute registration, and presenters are required to register for the conference separately. Please carefully read the guidelines before submitting your abstract.
※ After submission, you can review and modify your abstracts at 'My page-Abstract Submission' until the submission deadline.
Regular Abstract | “Regular Abstract” refers to all types of oncology-related research that are eligible for submission. |
---|---|
Trials in Progress Abstract |
“Trials in Progress Abstract” refers to ongoing trials that have not reached prespecified endpoints for analysis that are eligible for submission. |Trials in Progress abstracts that include results or preliminary data will be rejected without further review. It should be organized according to two sections: Backgrounds and Methods. |
Encore Abstract |
“Encore Abstract” refers to abstracts presented in another congress after September 27, 2024, but with updated data. • Encore submissions must have been presented solely in abstract form, including publication in conference proceedings. (Submissions which have already been published in the full publication form in journals will NOT be accepted.) • Include significant additional data from the previous presentation (as determined by the review committee). • Include the abstract title, co-authors listed, the full abstract, and indicate if this is an encore presentation and, if so, where it was previously presented. This information should be presented both in the abstract and on the poster. It is the sole responsibility of the author to follow these rules. The first author will be responsible for obtaining, and, upon request, showing proof that written permission has been obtained from the copyright holder of the original abstract publication(s). |
해외 지원 의무 초록 | This type is only for KSMO Members. |
Title | Abstract title should be less than 30 words. Spaces do not count as characters. |
---|---|
Author | You can enter up to 30 authors. |
Abstract Body |
The abstract body text should be structured chronologically into four sections: Background, Methods, Results, and Conclusions. In the case of a “Trials in Progress Abstract,” it should be organized according to two sections: Background and Methods. |
Keywords | 3 keywords which the first word begins with a capital letter. |
Tables and Images | No tables, graphs or images are allowed. |
Breast Cancer | Local/Regional Disease |
---|---|
DCIS/LCIS/Premalignant Lesions | |
Metastatic Disease | |
Other Breast Cancer | |
Central Nervous System Tumor | Brain Metastases |
Primary CNS Tumors–Glioma | |
Primary CNS Tumors–Non-Glioma | |
Developmental Therapeutics | Antibodies |
Immunotherapy | |
Circulating Biomarkers | |
Immunobiology | |
New Targets and New Technologies | |
Chemotherapy and Antibody-Drug Conjugates | |
Molecular Diagnostics and Imaging | |
Pharmacology/Pharmacodynamics/Pharmacogenetics | |
Tissue-Based Biomarkers | |
Vaccines | |
Radiopharmaceuticals | |
Small Molecules | |
Colorectal and Anal Cancer | Anal Cancer |
Colorectal Cancer–Advanced/Metastatic Disease | |
Colorectal Cancer–Local-Regional Disease | |
Other Colorectal and Anal Disease | |
Stomach Cancer and Esophageal Cancer | Stomach Cancer–Advanced/Metastatic Disease |
Stomach Cancer–Local-Regional Disease | |
Esophageal Cancer–Advanced/Metastatic Disease | |
Esophageal Cancer–Local-Regional Disease | |
Other GI Cancer | |
Biliary Tract, Liver and Pancreatic Cancer | Biliary Tract Cancer–Local-Regional |
Biliary Tract Cancer–Advanced/Metastatic Disease | |
Hepatocellular Carcinoma–Local-Regional Disease | |
Hepatocellular Carcinoma–Advanced/Metastatic Disease | |
Pancreatic Cancer–Local-Regional Disease | |
Pancreatic Cancer–Advanced/Metastatic Disease | |
Neuroendocrine/Carcinoid | |
Other GI Cancers | |
Kidney and Bladder Cancer | Kidney Cancer |
Urothelial Cancer–Advanced/Metastatic Disease | |
Urothelial Cancer–Local-Regional Disease | |
Other GU Kidney and Bladder Cancer | |
Prostate, Testis and Penile Cancer | Germ Cell/Testicular Cancer |
Penile Cancer | |
Prostate Cancer–Advanced Disease | |
Prostate Cancer–Local-Regional Disease | |
Other Prostate, Testicular, and Penile Disease |
Gynecologic Cancer | Cervical Cancer |
Ovarian Cancer | |
Uterine Cancer | |
Other Gynecologic Cancer | |
Head and Neck Cancer | Advanced/Metastatic Disease |
---|---|
Local-Regional Disease | |
Other Head and Neck Cancers (Salivary, Thyroid) | |
Lung Cancer | Non–Small Cell Lung Cancer - Local-Regional Disease |
Non–Small Cell Lung Cancer - Advanced/Metastatic Disease | |
Small Cell Lung Cancer | |
Mesothelioma | |
Thymic Malignancies | |
Other Lung Cancers | |
Melanoma and Skin Cancer | Local-Regional Disease |
Advanced/Metastatic Disease | |
Other Melanoma/Skin Cancers | |
Etiology, Epidemiology, Prevention and Genetics | Etiology/Epidemiology |
Germline Genetic Testing | |
Health Promotions/Behaviors | |
Hereditary Cancer Syndromes | |
Cancer Prevention | |
Sarcoma | Gastrointestinal Stromal Tumors (GIST) |
Bone Tumors | |
Soft Tissue Tumors | |
Symptom Science, Palliative Care and Others | Cardio-Oncology |
End-of-Life Care | |
Late and Long-Term Adverse Effects | |
Palliative Care and Symptom Management | |
Toxicities–Prevention and Management Strategies | |
Quality Care/Health Services Research | |
Clinician Burnout and Wellness | |
Medical Education | |
Pathobiology of Symptoms | |
Psychosocial and Communication Research | |
Survivorship | |
Geriatric Oncology |
초록 접수 마감일 : 5월 9일(금), 2025
초록 채택 공지일 : 7월 7일 (월), 2025
초록은 온라인으로 제출 가능하며, 제출된 초록은 KSMO 2025 학술위원회의 심사를 거쳐 수락여부가 최종 확정됩니다.
초록 제출과는 별개로 대회 등록을 진행해 주셔야 하며, 발표자는 반드시 별도로 등록해 주셔야 합니다.
※ 초록제출 후, 접수 마감일까지 'My page-Abstract Submission' 페이지에서 확인 및 수정이 가능합니다.
Regular Abstract | “Regular Abstract” refers to all types of oncology-related research that are eligible for submission. |
---|---|
Trials in Progress Abstract |
“Trials in Progress Abstract” refers to ongoing trials that have not reached prespecified endpoints for analysis that are eligible for submission. |Trials in Progress abstracts that include results or preliminary data will be rejected without further review. It should be organized according to two sections: Backgrounds and Methods. |
Encore Abstract |
“Encore Abstract” refers to abstracts presented in another congress after September 27, 2024, but with updated data. • Encore submissions must have been presented solely in abstract form, including publication in conference proceedings. (Submissions which have already been published in the full publication form in journals will NOT be accepted.) • Include significant additional data from the previous presentation (as determined by the review committee). • Include the abstract title, co-authors listed, the full abstract, and indicate if this is an encore presentation and, if so, where it was previously presented. This information should be presented both in the abstract and on the poster. It is the sole responsibility of the author to follow these rules. The first author will be responsible for obtaining, and, upon request, showing proof that written permission has been obtained from the copyright holder of the original abstract publication(s). |
해외 지원 의무 초록 | This type is only for KSMO Members. |
Title | 발표제목은 최대 30단어까지 가능하며, 공백은 포함되지 않습니다. |
---|---|
Author | 최대 30명까지 입력 가능합니다. |
Abstract Body |
초록의 본문은 Background, Methods, Results, Conclusions 4가지로 구성되어야 합니다. 단. TIP 초록은 Background, Methods으로 구성됩니다. |
Keywords | 3개의 키워드를 입력하고, 키워드 시작은 대문자로 시작합니다. |
Tables and Images | 초록 내 표, 그림, 그래프 삽입은 불가합니다.초록 내 표, 그림, 그래프 삽입은 불가합니다. |
Breast Cancer | Local/Regional Disease |
---|---|
DCIS/LCIS/Premalignant Lesions | |
Metastatic Disease | |
Other Breast Cancer | |
Central Nervous System Tumor | Brain Metastases |
Primary CNS Tumors–Glioma | |
Primary CNS Tumors–Non-Glioma | |
Developmental Therapeutics | Antibodies |
Immunotherapy | |
Circulating Biomarkers | |
Immunobiology | |
New Targets and New Technologies | |
Chemotherapy and Antibody-Drug Conjugates | |
Molecular Diagnostics and Imaging | |
Pharmacology/Pharmacodynamics/Pharmacogenetics | |
Tissue-Based Biomarkers | |
Vaccines | |
Radiopharmaceuticals | |
Small Molecules | |
Colorectal and Anal Cancer | Anal Cancer |
Colorectal Cancer–Advanced/Metastatic Disease | |
Colorectal Cancer–Local-Regional Disease | |
Other Colorectal and Anal Disease | |
Stomach Cancer and Esophageal Cancer | Stomach Cancer–Advanced/Metastatic Disease |
Stomach Cancer–Local-Regional Disease | |
Esophageal Cancer–Advanced/Metastatic Disease | |
Esophageal Cancer–Local-Regional Disease | |
Other GI Cancer | |
Biliary Tract, Liver and Pancreatic Cancer | Biliary Tract Cancer–Local-Regional |
Biliary Tract Cancer–Advanced/Metastatic Disease | |
Hepatocellular Carcinoma–Local-Regional Disease | |
Hepatocellular Carcinoma–Advanced/Metastatic Disease | |
Pancreatic Cancer–Local-Regional Disease | |
Pancreatic Cancer–Advanced/Metastatic Disease | |
Neuroendocrine/Carcinoid | |
Other GI Cancers | |
Kidney and Bladder Cancer | Kidney Cancer |
Urothelial Cancer–Advanced/Metastatic Disease | |
Urothelial Cancer–Local-Regional Disease | |
Other GU Kidney and Bladder Cancer | |
Prostate, Testis and Penile Cancer | Germ Cell/Testicular Cancer |
Penile Cancer | |
Prostate Cancer–Advanced Disease | |
Prostate Cancer–Local-Regional Disease | |
Other Prostate, Testicular, and Penile Disease |
Gynecologic Cancer | Cervical Cancer |
Ovarian Cancer | |
Uterine Cancer | |
Other Gynecologic Cancer | |
Head and Neck Cancer | Advanced/Metastatic Disease |
---|---|
Local-Regional Disease | |
Other Head and Neck Cancers (Salivary, Thyroid) | |
Lung Cancer | Non–Small Cell Lung Cancer - Local-Regional Disease |
Non–Small Cell Lung Cancer - Advanced/Metastatic Disease | |
Small Cell Lung Cancer | |
Mesothelioma | |
Thymic Malignancies | |
Other Lung Cancers | |
Melanoma and Skin Cancer | Local-Regional Disease |
Advanced/Metastatic Disease | |
Other Melanoma/Skin Cancers | |
Etiology, Epidemiology, Prevention and Genetics | Etiology/Epidemiology |
Germline Genetic Testing | |
Health Promotions/Behaviors | |
Hereditary Cancer Syndromes | |
Cancer Prevention | |
Sarcoma | Gastrointestinal Stromal Tumors (GIST) |
Bone Tumors | |
Soft Tissue Tumors | |
Symptom Science, Palliative Care and Others | Cardio-Oncology |
End-of-Life Care | |
Late and Long-Term Adverse Effects | |
Palliative Care and Symptom Management | |
Toxicities–Prevention and Management Strategies | |
Quality Care/Health Services Research | |
Clinician Burnout and Wellness | |
Medical Education | |
Pathobiology of Symptoms | |
Psychosocial and Communication Research | |
Survivorship | |
Geriatric Oncology |